Depression & Alcohol Dependence Risk and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process · /methodology/editorial-process Last reviewed: 2026-05-29
This page contains general information only. For personal health decisions, consult a qualified clinician.
Depression and alcohol dependence co-occurrence is a genetic and neurobiological pattern in which inherited variants influence susceptibility to both major depression and alcohol use disorder simultaneously — not as two separate risks, but as a shared neurological vulnerability rooted in the brain's reward circuitry. Heritability estimates for each condition individually range from 30% to 50%, and the two disorders co-occur at rates far above chance. Below: the genes that shape shared reward-circuit architecture, what genome-wide research has revealed about this comorbidity, how overlap in these conditions manifests in daily life, and evidence-backed steps that may support brain health across both dimensions.
What is depression and alcohol dependence risk?
Depression and alcohol dependence co-occurrence refers to the well-documented tendency for major depressive disorder (MDD) and alcohol use disorder (AUD) to arise together in the same individual. Epidemiological data show that people with MDD are roughly twice as likely to develop AUD, and vice versa. Genome-wide association studies (genome-wide studies that scan thousands of genetic markers across the full genome) have revealed that a meaningful portion of this overlap has a genetic basis — shared variants influencing the same neural circuits, not simply one condition causing the other.
The ExomeDNA result for this trait reflects the aggregated weight of common genetic variants associated with the combined MDD-plus-AUD phenotype, drawn from research into people who experienced both conditions. A higher polygenic score on this trait indicates that more of these shared-risk variants are present in your genome. It does not mean depression or alcohol dependence is inevitable — environment, life circumstances, and personal choices all play decisive roles.
The genetics behind depression and alcohol dependence risk
Six genes emerge from the research literature as contributors to the shared neurobiological terrain of MDD and AUD. Three of them operate directly inside the reward circuitry; two connect through metabolic and signaling pathways; one links to the body's alcohol-processing machinery.
EBF1 — the gene that shapes your reward circuit cells. EBF1 (Early B-Cell Factor 1) is a transcription factor — a protein that switches other genes on or off during development. Its best-known role is in producing immune B lymphocytes, but EBF1 has a second, less widely appreciated function: it is critical for specifying D1 and D2 medium spiny neurons (MSNs) in the striatum during fetal brain development. Medium spiny neurons are the primary cellular targets of dopamine in the brain's reward pathway. The nucleus accumbens — the ventral portion of the striatum — is the hub where reward-seeking behavior, motivation, and pleasure processing converge.
In the context of depression-AUD comorbidity, EBF1's role in MSN specification is mechanistically compelling. Depression is characterized in part by anhedonia — a blunted reward response in which experiences that once felt pleasurable no longer register as rewarding. Alcohol use disorder, by contrast, involves escalated reward-seeking and the deeply dysphoric state that emerges when alcohol (and the dopamine release it triggers) becomes unavailable. Both conditions, despite their surface-level differences, reflect dysregulation of the same striatal circuitry. Variants near EBF1 that subtly alter the specification of MSN populations during development may create a shared striatal vulnerability — a brain reward system that processes both pleasure and withdrawal differently from the population average.
ESRRG — mitochondrial energy in dopaminergic neurons. ESRRG (Estrogen-Related Receptor Gamma) is a nuclear receptor expressed prominently in the striatum, hypothalamus, and brainstem. It regulates genes involved in mitochondrial biogenesis and fatty acid oxidation — the machinery that generates the ATP energy required for sustained neuronal activity. In dopaminergic and striatal circuits, mitochondrial capacity determines how reliably neurons can fire and release neurotransmitters under metabolic demand.
ESRRG also connects estrogen-related signaling to mitochondrial function, a link with potential relevance to the well-documented sex differences in these two conditions: women experience MDD at roughly twice the rate of men, while men show higher rates of AUD. Variants in ESRRG may affect the energetic resilience of reward-circuit neurons, influencing both mood stability and the neural capacity for sustained dopamine signaling.
ADH1A and ADH1B — alcohol metabolism and the reward-dysphoria link. ADH1A and ADH1B encode alcohol dehydrogenase enzymes — proteins that catalyze the first step in breaking down ethanol into acetaldehyde. These genes are discussed in depth on the Alcohol Flush and Alcohol Metabolism trait pages. Their presence in a combined depression-plus-AUD genome-wide study carries a distinct implication: variants that alter how quickly alcohol is metabolized influence not only direct AUD risk, but also the neurochemical loop between alcohol exposure and mood. Alcohol initially raises dopamine and serotonin levels; faster or slower metabolism changes how long this neurochemical effect lasts and how severe the subsequent dysphoric rebound becomes. The shared metabolic pathway may represent one mechanism through which alcohol-metabolism genetics influences both reward dysphoria and AUD susceptibility.
ANXA2 — neurotransmitter release dynamics. ANXA2 (Annexin A2) is a calcium-dependent membrane protein involved in vesicle exocytosis — the cellular process by which neurotransmitters packaged inside vesicles are released into synaptic junctions. In neurons, ANXA2 participates in the membrane dynamics that regulate how efficiently dopamine, serotonin, and norepinephrine are released. Subtle alterations in neurotransmitter release machinery could contribute to the reward-circuit tone differences observed in both depression and AUD.
BBS4 — hypothalamic circuits connecting stress, appetite, and mood. BBS4 is a component of the BBSome complex, which traffics receptors — including the leptin receptor — to cilia on hypothalamic neurons. The hypothalamus integrates signals about stress, appetite, energy balance, and mood; hypothalamic dysfunction is implicated in both the vegetative symptoms of depression (disrupted appetite, sleep, and energy) and the stress-reactivity patterns seen in AUD. BBS4 variants that alter hypothalamic receptor signaling may contribute to the overlapping disruptions in stress and appetite regulation shared between these conditions.
Genome-wide study of combined MDD and AUD — A 2017 study (Zhou 2017) identified genetic variants jointly associated with major depression and alcohol dependence, demonstrating that shared genetic architecture contributes to the co-occurrence of these two conditions beyond chance overlap.[1]
Co-occurrence far above chance — People with major depressive disorder are substantially more likely to develop alcohol use disorder, and vice versa, a pattern that genome-wide studies suggest reflects shared inherited neurobiological vulnerability rather than one condition simply causing the other.[1]
What the research says
Research base: Moderate. The evidence base for this trait rests on a cross-diagnostic genome-wide association study examining individuals who experienced both major depression and alcohol dependence (Zhou 2017).[1] This design — explicitly targeting the comorbid phenotype rather than either condition separately — is scientifically meaningful because it captures variants specifically associated with the shared vulnerability, rather than those relevant to only one condition.
The genome-wide study identified several associated loci, including regions near EBF1, ESRRG, ADH1A, ADH1B, ANXA2, and BBS4. Because this research is based on a single study in this combined-phenotype design, the confidence tier for this trait is rated moderate. Individual studies in psychiatric genetics, even large ones, require independent replication across diverse populations before associations are considered definitive.
Broader context from the depression genetics literature supports the biological plausibility of reward-circuit involvement in MDD. Multiple large-scale genome-wide studies of major depressive disorder individually (not combined with AUD) have implicated related neurodevelopmental and neurochemical pathways.[2–11] The EBF1 striatal MSN specification angle represents a genuinely novel mechanistic hypothesis for why depression and AUD so commonly travel together — one not prominently featured in prior depression-only or AUD-only genetic pages.
For a detailed account of how ExomeDNA interprets genome-wide association evidence and translates it into polygenic scores, see our methodology page.
It is worth noting that this trait's polygenic score reflects population-level associations. Individual genetic results are probabilistic, not deterministic, and should be understood as one input among many — not as a forecast of personal health outcomes.
How depression and alcohol dependence risk affects you
Understanding the shared genetic architecture of depression and AUD has practical implications that extend beyond knowing a single risk number.
Anhedonia and reward sensitivity. Both conditions involve the brain's capacity to register reward and motivation. In depression, this often manifests as anhedonia — a reduced ability to feel pleasure from activities that were previously enjoyable. In AUD, the same circuitry is engaged differently: alcohol temporarily restores a sense of reward, which is part of why it becomes compelling when natural reward-seeking feels blunted. People with higher genetic loading on this trait may have a reward circuit that requires more intentional support through activities that reliably activate dopamine pathways — exercise, social connection, creative engagement — rather than chemical shortcuts.
The withdrawal-dysphoria cycle. Alcohol use provides temporary relief from depressive symptoms; withdrawal deepens those symptoms, increasing the motivation to drink. This cycle has a neurochemical basis — involving dopamine, serotonin, GABA, and glutamate — with a genetic dimension. Understanding this shared architecture can reframe alcohol use in the context of mood as a neurobiological loop rather than a moral failing.
Sex differences in how risk manifests. ESRRG's connection to estrogen-related signaling is consistent with the different ways genetic risk expresses across sexes: women are more likely to experience MDD, while men show higher rates of AUD. The same variants may interact differently with hormonal milieu, social context, and stress response systems.
The comorbidity is common and treatable. Co-occurring depression and alcohol use disorder responds well to integrated treatment addressing both conditions simultaneously. Treating either alone typically produces worse outcomes than integrated approaches.
Working with your depression and alcohol dependence result
If your result indicates higher polygenic loading for this trait, the following evidence-backed strategies are relevant to supporting reward-circuit health and resilience. These are general wellness considerations, not medical recommendations.
Prioritize aerobic exercise consistently. Exercise robustly increases dopamine signaling and BDNF (brain-derived neurotrophic factor) in striatal circuits, directly engaging the same pathways that EBF1-specified MSNs govern. Studies consistently associate regular aerobic exercise with reduced depressive symptoms and decreased alcohol craving.[1]
Seek integrated support if both depression and alcohol use are concerns. Evidence strongly supports integrated behavioral treatment — approaches that address both MDD and AUD simultaneously — over sequential single-condition treatment. If you are working with a clinician, this framing is worth raising explicitly.
Monitor alcohol's role in mood regulation. Because the same circuits govern both reward-seeking and mood, people with higher genetic loading on this trait may be more likely to use alcohol as mood regulation. Tracking the relationship between alcohol use and next-day mood (anhedonia, irritability, motivation) can make this cycle visible and actionable.
Support mitochondrial function in neurons. The ESRRG pathway connects neuronal energy metabolism to dopaminergic circuit function. Lifestyle factors with documented effects on mitochondrial health — regular sleep, omega-3 fatty acid intake, resistance training, caloric balance — may be relevant to maintaining the energy supply that dopaminergic and striatal neurons require.[1]
Leverage social connection as a reward-circuit activator. Social bonding reliably activates nucleus accumbens dopamine release through endogenous opioid and oxytocin mechanisms. For people whose reward circuits may have a different baseline tone, prioritizing quality social connection is among the most evidence-consistent behavioral interventions.
Discuss your genetic result with a clinician if relevant. Polygenic information about depression-AUD comorbidity risk can be a useful conversation anchor with a mental health provider or primary care clinician, particularly for those with personal or family history of either condition.
Related traits and genes
The reward-circuit vulnerabilities captured here overlap with traits in the mental wellness, addiction, and metabolic categories.
Mental wellness:
- Major Depression Genetic Risk
- Anxiety Genetic Risk
- Stress Response and Cortisol Regulation
Cross-category:
- Alcohol Metabolism (ADH1B)
- Dopamine Sensitivity (COMT Val158Met)
Frequently asked questions
Does a high result on this trait mean I will develop depression or alcohol dependence?
No. A higher polygenic score for this trait means that more of the common genetic variants associated with the combined depression-and-AUD phenotype are present in your genome. It reflects a statistical tendency at the population level — not a personal prediction. The vast majority of people with high genetic loading for these traits do not develop either condition, and many people without high loading do. Genetics is one factor among many; environment, relationships, life experience, and personal choices all contribute substantially.
Why do depression and alcohol dependence occur together so often?
The co-occurrence of major depressive disorder and alcohol use disorder is one of the most common psychiatric comorbidities, and genome-wide research suggests shared genetic architecture plays a meaningful role (Zhou 2017).[1] Both conditions involve the brain's reward and motivation circuits — particularly the striatum and nucleus accumbens — and genes that shape how those circuits develop and function appear to confer risk for both simultaneously. This is distinct from one condition simply causing the other, though causal relationships between them also exist.
What makes EBF1 relevant to both depression and alcohol use disorder?
EBF1 is a transcription factor that, during brain development, helps specify the medium spiny neurons (MSNs) of the striatum — the cells that are the primary targets of dopamine in the reward pathway. Depression is associated with blunted reward-circuit activation (anhedonia), and alcohol use disorder involves escalated reward-seeking and dysphoric withdrawal when alcohol's dopamine-triggering effect is absent. Both reflect reward-circuit dysregulation; EBF1 variants that influence how MSNs are specified during development may create a shared striatal vulnerability to both conditions.
Is the research on this trait definitive?
The research base for this specific combined phenotype (MDD plus AUD) is rated moderate. The primary genome-wide study (Zhou 2017) identified associated variants in a cross-diagnostic design, but independent large-scale replication across diverse populations is needed before these associations are considered robust.[1] The broader evidence base for the genetic contribution to depression individually, and to AUD individually, is more extensive. This result is best understood as a signal warranting awareness, not a confirmed causal finding.
Can lifestyle choices change the effect of these genetic variants?
Genes do not determine outcomes — they influence probabilities, often in ways that interact substantially with environment. Regular aerobic exercise, consistent sleep, social connection, and limiting alcohol use all have documented effects on the very neural circuits that the genes associated with this trait influence. People with higher genetic loading for this trait are not destined for any particular outcome and have the same capacity to benefit from these interventions as anyone else.
Should I speak with a clinician about this result?
Those with personal history of depression or concerns about their relationship with alcohol may find it useful to discuss this genetic result with a qualified clinician — a primary care physician, psychiatrist, or licensed therapist — as a starting point for a broader conversation about mental health and wellness. This result is informational context, not a clinical evaluation. Clinicians with experience in integrated treatment for co-occurring depression and AUD can offer personalized guidance that this page cannot.
References
- Zhou H, et al. Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression. JAMA Psychiatry. 2017. PMID: 29071344.
Data sources:
- GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
- Open Targets Platform (CC0 1.0, accessed 2026-05-29)
- ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
- ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)
ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.